Aclarion, INC 10-Q quarterly reports

Aclarion, Inc. reported Q2 2026 results showing increased revenue driven by UK market growth, but also a substantial rise in operating expenses, leading to a wider net loss.

Aclarion, Inc. reported a 61.3% revenue increase for the nine months ended September 30, 2025, driven by UK market expansion, while securing over $20 million in capital to extend its operational runway through Q1 2027 despite rising operating losses.

Aclarion, Inc. reported a significant increase in revenue and cash reserves for Q2 2025, driven by UK market expansion, despite widening net losses and increased operating expenses.

Aclarion Inc.'s Q1 2025 shows revenue growth driven by increased patient scans, alongside significant financing activities including public and direct offerings.

Aclarion Inc.'s Q3 2024 results show a decrease in revenue and ongoing losses, alongside efforts to address financial and compliance issues.

Aclarion Inc. reports a net loss of $3.6 million for the first half of 2024, alongside a decrease in revenue and ongoing efforts to address financial challenges.

Aclarion Inc. reported a net loss of $2.4 million for the first quarter of 2024, alongside a decrease in revenue and ongoing concerns about its ability to continue as a going concern.